Meningioma
The Brain Tumour Charity Support Group
Meningioma Support
Beyond Brain Tumours
Online brain tumour support groups
25 Providers Who Treat Meningiomas (Cleveland Clinic)
https://my.clevelandclinic.org/services/meningioma-treatment#featured-provider-panel
(Technical Stuff) The basic research Q&A: what we found for meningioma papers involving mebendazole.
Mebendazole appears in both preclinical meningioma studies and review articles discussing meningioma repurposing, whereas ivermectin appears in broader cancer/parasitic-disease literature rather than meningioma-specific work. I did not find any meningioma-specific paper that includes ivermectin.
Repurposed antiparasitic drugs for meningioma
Meningioma literature is dominated by mebendazole, and I did not find a meningioma-specific study for ivermectin. What was discovered:
What about ivermectin?
Ivermectin is discussed for other infections and other cancers, but not in a meningioma-specific study.
The closest meningioma-related antiparasitic evidence is still mebendazole, not ivermectin.
In this research, Mebendazole is the one with direct meningioma evidence in this dataset; ivermectin is not supported by a meningioma-specific paper here.
Which meningioma studies tested mebendazole in preclinical models?
Mebendazole in preclinical meningioma research:
The only explicit meningioma preclinical study identified in the available evidence is:

The 2023 CNS tumor repurposing review also describes mebendazole as having meningioma activity in cell-line/preclinical work, including inhibition of hedgehog signaling, VEGFR2 blockade, tubulin disruption, and pro-apoptotic effects in meningioma cells.
The 2026 systematic review similarly states that mebendazole has preclinical evidence in brain tumors, including meningioma, with tumor growth suppression and survival extension.
What clinical trials have included mebendazole for meningioma?
No meningioma clinical trial in the retrieved evidence actually tested mebendazole in meningioma patients; the meningioma-specific mebendazole evidence here is preclinical only, while the human trials I found were in glioma, not meningioma. Mebendazole appears in meningioma preclinical work and in clinical trials for other brain tumors, especially glioma.
Are there any meningioma studies on other repurposed antiparasitic drugs?
Closest meningioma-relevant papers
Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma showed that mebendazole alone and with radiation increased survival and produced stronger apoptosis plus lower tumor and vascular proliferation in meningioma models.
A later meningioma radiosensitization paper again cites mebendazole as a prior preclinical meningioma radiosensitizer and notes that its clinical radiosensitizing effect is still unknown.
A 2026 meningioma study reported that mebendazole reduced invasion in patient-derived 3D spheroids, preventing invasion in most samples and implicating Rho GTPase/cytoskeletal effects.
Reviews on brain-tumor repurposing describe mebendazole as a candidate because it crosses the blood-brain barrier and has preclinical activity across brain tumors, including meningioma.
Mebendazole in patient-derived models
The only meningioma study in the retrieved evidence that tested mebendazole in a patient-derived model is Mebendazole Attenuates Cellular Invasion in a 3D Culture Model of Meningioma by Disrupting Rho-GTPase-Mediated Microtubule Function (2026), which used primary patient-derived meningioma cell lines grown as 3D spheroids and found that mebendazole prevented invasion in 89% of samples.





